1. Home
  2. AAPG vs EVO Comparison

AAPG vs EVO Comparison

Compare AAPG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ascentage Pharma Group International American Depository Shares

AAPG

Ascentage Pharma Group International American Depository Shares

N/A

Current Price

$30.35

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.99

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAPG
EVO
Founded
2009
1993
Country
China
Germany
Employees
567
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
1.1B
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
AAPG
EVO
Price
$30.35
$2.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$48.50
$7.00
AVG Volume (30 Days)
4.4K
105.3K
Earning Date
11-19-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$54,524,554.00
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
$368.64
$8.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.50
$2.84
52 Week High
$48.45
$5.10

Technical Indicators

Market Signals
Indicator
AAPG
EVO
Relative Strength Index (RSI) 42.17 40.74
Support Level $28.50 $2.86
Resistance Level $32.96 $3.24
Average True Range (ATR) 0.70 0.10
MACD -0.05 0.01
Stochastic Oscillator 40.31 28.57

Price Performance

Historical Comparison
AAPG
EVO

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: